XACT Robotics® Recognized for 2021 Technology Innovation Leadership

North American Percutaneous Procedure System Industry Excellence in Best Practices

As COVID fades the Life Sciences see a bigger and brighter future.

Moshe Bar Siman Tov, the former Director General of the Ministry of Health, visited Shizim Group to explore possible future collaboration.

Shizim Group and RITS – The Research Institute of Tsinghua University in Shenzhen, China, Signed Collaboration Agreement

We are happy to announce that Shizim Group and RITS – The Research Institute of Tsinghua University in Shenzhen, China, signed collaboration agreement to setup a highway for Medical Device and Digital Health technologies between Israel and China.

The Parties will work together on identifying Israeli technologies, suitable for the Chinese/Asian markets, provide them with supports in research and development, manufacturing, marketing, business development and commercialization in China and other global markets.

Shizim and RITS will also explore possible cooperation in the fields of executive education in healthcare innovations and entrepreneurship.

About RITS:

The Research Institute of Tsinghua University in Shenzhen (RITS) was founded in December 1996. RITS is positioned to serve as a model of Tsinghua University in the promotion of the technological, economic and social development in local region, also as a cradle for high-tech listed companies in Pearl River Delta, as well as an important base for talent training in South China. RITS strives to establish an innovation incubation system and an industrial investment platform open to both China and abroad, cultivating strategic emerging industries.

About Shizim Group:

Shizim Group is a leading Health-Tech holding group, with two Innovation Centers, ShizimXL for Medical Devices and ShizimVS for Digital Health technologies with extensive industry expertise and network, including companies active in diverse areas such as entrepreneurship, clinical research, regulatory affairs, R&D support, medical device and pharma products marketing and distribution, business development and more.

Shizim will support access to its “world class” portfolio companies and identifying other high-end value technologies available in Israel.

The award, presented in recognition of a “pioneering masterpiece” for Israeli society, was dedicated this year to contributing to innovation and industry. The Yigal Alon Prize Committee decided to award the prize this year to Prof. Moshe Shoham of the Technion – Pioneers of Robotics in Israel.

We are happy to inform that eHV, the leading Digital Health incubator in Israel, has completed an investment in Skelable – which is creating an advanced robotics treatment system that allows stroke patients to pursue advanced rehabilitation and recovery therapeutics at the point of care and also from the comfort of their home.

Skelable’s exoskeletal robotic glove, powered by AI-driven data and insights, will introduce a more effective and affordable solution for patients, therapists, and coverage providers.

Post-stroke rehabilitation is an underserved sector of neurology and Skelable is a game-changing company that introduces strong AI abilities combined with advanced robotics and telemedicine capabilities. COVID-19 is another growth driver for this type of solution and we are sure Skelable will create significant value for all its stakeholders.

We wish Avi, Geva and the team plenty of success!!

Contact: Avi Werner, CEO – avi@skelable.com

About eHealth Ventures

eHealth Ventures is a multinational consortium of world-class medical organizations, industry leaders, and seasoned financial investors. Partners include Maccabi – Israel’s leading HMO, the Israeli Innovation Authority (IIA), Amgen – a global biotechnology leader, Medison Pharma – a leading Israeli pharmaceutical company and SCI – a major Chinese VC fund.

eHV is focused on Digital Diagnostics and Home Care, has reviewed over 1200 projects and invested in 14 innovative companies.

Contact: info@ehv.health

HINGHAM, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) — The continued progression of Microbot Medical Inc.’s (Nasdaq: MBOT) LIBERTY™ Robotic System was further demonstrated as the Company announced the successful completion of an additional feasibility animal study using the world’s first fully disposable surgical robotic system. The study end points included navigating to a clot, crossing the clot, deploying a stent retriever, and manually retrieving an arterial clot in a live pig. All the end points were met with no intraoperative adverse events. The animal feasibility studies to date, support the Company’s assertion that LIBERTY will potentially allow physicians to safely and easily conduct catheter-based peripheral and neurovascular procedures remotely, avoiding radiation exposure, physical strain and the risk of cross contamination.

“As we continue to evaluate LIBERTY in the hands of leading clinicians, the system is performing to our expectations and achieving the desired clinical and usability outcomes,” commented Harel Gadot, Chief Executive Officer, President, and Chairman. “Additional studies are planned throughout the coming year to allow us to achieve our regulatory goals.”

The procedure was performed by Dr. Gal Yaniv, a recently added member of the Company’s Scientific Advisory Board (SAB), who also serves as Director of Endovascular Neurosurgery at Sheba Tel HaShomer City of Health and Chief Medical Officer of Aidoc Medical, a full body imaging AI software firm. Dr. Yaniv conducted the procedure and the results demonstrated robust navigation capabilities and intuitive usability.

Mr. Gadot will be presenting an overview of the Company later today at 2:00pm ET. The live and archived replays of the presentation may be accessed via the ‘Investors’ section, under ‘Presentation + Resources’ of the Company’s website at www.microbotmedical.com.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot’s current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).

Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available at http://www.microbotmedical.com.

Safe Harbor

Statements pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary closing conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY™ and SCS, the outcome of its studies to evaluate LIBERTY, SCS and other existing and future technologies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Investor Contact:

Michael Polyviou
EVC Group
mpolyviou@evcgroup.com
732-933-2754

Source: Microbot Medical

First Outpatient Facility in the U.S. to Offer Robotic Percutaneous Assistance

SARASOTA, FL – Always on the cutting edge of technology to enhance medical diagnosis and treatment, Sarasota Interventional Radiology (SIR-Florida), now at its new location in Lakewood Ranch, recently became the first outpatient medical facility in the U.S.to acquire the XACT ACE™ Robotic System for CT-guided interventional radiology procedures.

ACE is the world’s first and only hands-free robotic technology that combines advanced image-based procedure planning and navigation with robotic instrument insertion and steering capabilities, enabling the delivery of site-specific percutaneous solutions with accuracy, consistency, and efficiency. At this time, SIR-Florida is performing biopsies with ACE and will expand the use of this technology to ablations and other procedures in the future.

“Our philosophy is to provide exemplary care at SIR-Florida, and the XACT ACE™ Robotic System will help us to deliver on our mission to bring unparalleled service to our patients in the most efficient way,” said Gerald E. Grubbs, MD, SIR-Florida’s Founder and Medical Director. “We are proud to be the first non-hospital provider in Florida to offer the XACT ACE™ Robotic system for accurate, consistent, and efficient procedural outcomes while delivering safe, cost-effective, and exceptional care to our patients.”

The XACT ACE™ Robotic system is compatible with a broad range of imaging modalities, and Its small footprint and high mobility features enable healthcare providers to efficiently treat a broad range of patient care needs in multiple areas of the body. “Utilizing the XACT ACE™ Robotic System in an outpatient facility is a paradigm shift in the way interventional procedures are performed, which will elevate interventional radiology standards and ultimately benefit the patients,” stated Harel Gadot, Founder, Executive Chairman and President, XACT Robotics.

About Sarasota Interventional Radiology

Sarasota Interventional Radiology (SIR-Florida) is Florida’s premier interventional radiology practice that focuses on nonsurgical and minimally invasive methods to diagnose and treat pain, illness, and disease. SIR-Florida is also the area’s preferred one-stop imaging center that offers the most revolutionary technology for general radiology needs.

For more information, visit our website at www.sir-florida.com or call 941.241.2595.

About XACT Robotics

Founded in 2013, XACT Robotics is a privately held company with offices in Hingham, MA. XACT Roboticsis advancing the field of radiology by pioneering the first hands-free robotic system that combines image-based planning and navigation with instrument insertion and steering capabilities.

For further information, visit www.xactrobotics.com.

Cann10, a leading company in medical cannabis industry in Israel, is happy to announce of reaching an agreement with Seach, signed on 31 of December 2020, by which it acquires Seach’s shares. The acquisition was made by Yossi Bornstein and Kobi Caspi, the owners of the Shizim Group.
Shizim is a leading Israeli company in the field of medical innovations, healthcare technologies, medical devices, and digital health. It owns a group of companies providing medical services in the biomed sector.

Cogniguard updated that the European Patent Examiner, informed the company about its intention to issue a Notice of Allowance for its patent application for treating various neurological disorders

Cogniguard Ltd., a clinical stage company that is developing noninvasive Vagal Nerve Stimulation (VNS) for the treatments for Alzheimer’s disease, Cognitive impairment and Epilepsy, updated that the European Patent Examiner, informed the company about its intention to issue a Notice of Allowance for its patent application for treating various neurological disorders using its synchronized nerve activation technology.

This is in continue to the United States Patent and Trademark Office (USPTO) Notice of Allowance issued a few months ago.

Cogniguard, one of ShizimXL’s portfolio companies, is conducting its R&D activities in Lodz, Poland is developing three applications:

• VStim^TM – Non-invasive neuromodulation platform used to promote memory capabilities in healthy subjects.

• VGuard^TM – Non-invasive neuromodulation therapy for AD to reduce or stop cognitive decline based on Vstim^TM platform.

• StimulEp^TM – Non-invasive neuromodulation therapy to suppress or stop nightly epileptic seizures based on Vstim^TM platform.